Top broker names Temple & Webster (ASX:TPW) share price as a buy

Here's why Temple & Webster shares are rated as buys…

| More on:
A man eases back onto his sofa, happy with the relaxed vibe from his furniture.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Temple & Webster Group Ltd (ASX: TPW) share price has been a strong performer over the last few weeks.

Since this time last month, the online furniture and homewares retailer's shares have stormed 17% higher.

This compares to a 1.3% gain by the S&P/ASX 200 Index (ASX: XJO) over the same period.

Why is the Temple & Webster share price on fire?

Investors have been bidding the Temple & Webster share price higher this month following the release of its full year results at the end of July.

For the 12 months ended 30 June, Temple & Webster delivered an 85% increase in revenue to $326.3 million and a 141% jump in EBITDA to $20.5 million.

A key driver of its growth in FY 2021 was another strong increase in customer numbers. At the end of the period, Temple & Webster's active customers were up 62% year on year to 778,000. This means the company added 100,000 new active customers in the second half of the financial year.

Positively, its strong form has continued early in the new financial year, with revenue increasing 39% over the prior corresponding period between 1 July to 24 July.

Can its shares go higher?

The good news is that the team at Morgan Stanley believe Temple & Webster's shares can still climb higher from here.

In response to its full year results, the broker retained its overweight rating and lifted its price target on Temple & Webster's shares to $16.00.

Based on the latest Temple & Webster share price of $13.60, this represents potential upside of almost 18% over the next 12 months.

Its analysts believe that Temple & Webster can grow its revenue by ~30% per annum in the coming years, putting it on course to hit $1 billion in revenue by FY 2026.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Temple & Webster Group Ltd. The Motley Fool Australia has recommended Temple & Webster Group Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A man in a suit smiles at the yellow piggy bank he holds in his hand.
Share Market News

Forget Westpac shares, these ASX ETFs could be better buys

Here's why these funds could be quality picks for investors looking for alternatives to the banks.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another tough day for investors.

Read more »

Rising real estate share price.
REITs

Macquarie names its top 4 ASX REITs to buy today

Macquarie expects these four dividend paying ASX REITs will all surge higher in 2026.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

Man with virtual white circles on his eye and AI written on top, symbolising artificial intelligence.
Broker Notes

Why this ASX AI stock could return 40% in 2026

Let's see which stock Bell Potter is tipping to rise strongly.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Share Market News

Analysts name 2 top ASX 200 shares to buy today

Leading investment experts name two quality ASX 200 shares to buy now.

Read more »

Woman leaping in the air and standing out from her friends who are watching.
Broker Notes

This ASX 200 gold stock has surged 77% in 2025. Here's why Macquarie expects it to leap another 23%

Macquarie forecasts 23% upside for this surging ASX gold stock, and that doesn’t include the dividends!

Read more »